Drug Trial Radar · NCT03374800
Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial
Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,800
Actual
Start
Jul 9, 2018
Primary completion
Oct 31, 2023
Study completion Jan 31, 2024
Sponsor
- Lead sponsor
- McMaster UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR); Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group; National Health and Medical Research Council, Australia
- First posted
- Dec 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients who are critically ill in the in the Intensive Care Unit (ICU), especially those who need a breathing machine, can develop ulcers in the stomach that bleed. To prevent bleeding, many such patients around the world receive a drug called pantoprazole that decreases acid production. However, today, compared to decades ago, critically ill patients rarely develop upper gastrointestinal bleeding. This decrease is likely due to modern medicine, better resuscitation and earlier feeding. There may also be harms associated with pantoprazole and other drugs that reduce acid levels in the stomach including lung infections (pneumonia) and bowel infections (Clostridioides difficile). Studies in this area are old and of modest quality. Therefore, it is difficult to know whether pantoprazole does decrease stomach bleeding these days, or whether the possible harms of lung and bowel infections are actually more common and more serious problems. The goal of this international study is to determine if, in critically ill patients using breathing machines, the use of pantoprazole is effective in preventing bleeding from stomach ulcers or whether it causes more problems such as lung infection (pneumonia) and bowel infection (Clostridioides difficile), or whether pantoprazole has no effect at all. Whether the harms are worth the benefits, and whether the benefits are worth the costs, will be determined by an economic analysis to inform patients, families, clinicians, and healthcare systems globally.
Conditions
- Gastrointestinal Hemorrhage (Clinically Important, Upper)
Interventions
Placebo (0.9% saline)Drug
normal saline
PantoprazoleDrug
40 mg powder for injection reconstituted with 0.9% saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of clinically important upper gastro-intestinal bleedingTime frame: 90 days (In ICU or resulting in ICU readmission, censored at 90 days after randomization)
- Primary Safety Outcome: 90 Day MortalityTime frame: 90 days post randomization
Locations
67 sites in 8 countries. Site status is shown where the registry gives one.
University of Nebraska - Nebraska Medical Center
Omaha, Nebraska
Bankstown-Lidcombe Hospital
Bankstown, New South Wales, Australia
Blacktown Hospital
Blacktown, New South Wales, Australia
Sutherland Hospital
Caringbah, New South Wales, Australia
Gosford Hospital
Gosford, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Royal Brisbane Womens Hospital
Brisbane, Queensland, Australia
Ipswich Hospital
Ipswich, Queensland, Australia
Mater Hospital
South Brisbane, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Bendigo Health
Bendigo, Victoria, Australia
Geelong University Hospital
Geelong, Victoria, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
Epworth Hospital
Melbourne, Victoria, Australia
Sociedade Hospitalar Angelina Caron
Campina Grande do Sul, Brazil
Beneficência Social Bom Samaritano
Governador Valadares, Brazil
Foothills Hospital
Calgary, Alberta, Canada
Peter Lougheed Hospital
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
Nanaimo Regional General Hospital
Nanaimo, British Columbia, Canada
Royal Columbian Hospital
New Westminster, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Vancouver Island Health Authority
Victoria, British Columbia, Canada
St. Boniface Hospital
Winnipeg, Manitoba, Canada
Health Science Center Winnipeg
Winnipeg, Manitoba, Canada
Grace Hospital
Winnipeg, Manitoba, Canada
Saint John Regional Hospital
Saint John, New Brunswick, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
William Osler Hospital, McKenzie Health, Brampton Civic Hospital
Brampton, Ontario, Canada
Brantford General Hospital
Brantford, Ontario, Canada
Cambridge Memorial Hospital
Cambridge, Ontario, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Hamilton Health Science Center - General Hospital
Hamilton, Ontario, Canada
Hamilton Health Science Center - Juravinski Hospital
Hamilton, Ontario, Canada
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.